文献速递消化系统肿瘤

MNK抑制通过降低eIF4E磷酸化和c-MYC表达使KRAS突变结直肠癌对mTORC1抑制敏感

MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.
PubMed 文献 · Cancer Discov · 2020-12-16

KRAS突变结直肠癌对治疗耐药,约占病例40%。研究利用Kras突变小鼠模型及小鼠和患者来源类器官,发现KRAS G12D突变通过MNK/eIF4E通路重编程翻译并持续表达c-MYC,遗传或小分子靶向该通路可抑制c-MYC使模型对雷帕霉素敏感。45%结直肠癌存在mTORC1和MNK高信号,与部分患者癌症特异性生存缩短3.5年相关。

要点

  • KRAS G12D突变通过MNK/eIF4E通路增加翻译起始并维持c-MYC表达。
  • 靶向MNK可抑制c-MYC,使KRAS G12D模型对mTORC1抑制剂雷帕霉素敏感。
  • 45%结直肠癌高信号mTORC1和MNK,与部分患者生存缩短3.5年相关。

核心结论

  • KRAS G12D突变通过MNK/eIF4E通路重编程翻译并维持c-MYC表达,联合靶向mTORC1和MNK可增敏KRAS突变结直肠癌。

研究设计与样本

  • 研究使用Kras突变小鼠模型以及小鼠和患者来源的类器官进行临床前研究。

主要发现

  • KRAS G12D突变从根本上重编程翻译,增加整体和mRNA特异性翻译起始。
  • 该过程通过MNK/eIF4E通路实现,导致c-MYC持续表达。
  • 遗传或小分子靶向该通路可抑制c-MYC,使KRAS G12D模型对雷帕霉素急性增敏。
  • 45%的结直肠癌存在mTORC1和MNK高信号,该特征与部分患者癌症特异性生存缩短3.5年相关。

关键数值与推荐

  • 45%的结直肠癌具有mTORC1和MNK高信号。
  • 该信号特征与部分患者癌症特异性生存缩短3.5年相关。

临床怎么用

  • 在KRAS突变结直肠癌中可考虑联合靶向mTORC1和MNK,尤其高信号mTORC1和MNK的患者人群可能获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KRAS-mutant colorectal cancers are resistant to therapeutics, presenting a significant problem for ∼40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS-mutant colorectal cancer. Using Kras-mutant mouse models and mouse- and patient-derived organoids, we demonstrate that KRAS with G12D mutation fundamentally rewires translation to increase both bulk and mRNA-specific translation initiation. This occurs via the MNK/eIF4E pathway culminating in sustained expression of c-MYC. By genetic and small-molecule targeting of this pathway, we acutely sensitize KRASG12D models to rapamycin via suppression of c-MYC. We show that 45% of colorectal cancers have high signaling through mTORC1 and the MNKs, with this signature correlating with a 3.5-year shorter cancer-specific survival in a subset of patients. This work provides a c-MYC-dependent cotargeting strategy with remarkable potency in multiple Kras-mutant mouse models and metastatic human organoids and identifies a patient population that may benefit from its clinical application. SIGNIFICANCE: KRAS mutation and elevated c-MYC are widespread in many tumors but remain predominantly untargetable. We find that mutant KRAS modulates translation, culminating in increased expression of c-MYC. We describe an effective strategy targeting mTORC1 and MNK in KRAS-mutant mouse and human models, pathways that are also commonly co-upregulated in colorectal cancer.This article is highlighted in the In This Issue feature, p. 995.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Knight JRP, Alexandrou C, Skalka GL, et al. MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discov. 2020. PMID: 33328217. doi:10.1158/2159-8290.CD-20-0652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。